BioXcel Therapeutics, Inc.
BTAIQ
$0.05
$0.009.56%
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -11.65% | -19.53% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -11.65% | -19.53% | |||
| Cost of Revenue | -92.23% | 784.38% | |||
| Gross Profit | 307.79% | -134.38% | |||
| SG&A Expenses | -0.03% | 88.99% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.52% | -1.03% | |||
| Operating Income | 0.29% | 0.57% | |||
| Income Before Tax | -15.93% | -1.16% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -15.93% | -1.16% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.93% | -1.16% | |||
| EBIT | 0.29% | 0.57% | |||
| EBITDA | -0.10% | 0.42% | |||
| EPS Basic | 9.81% | 6.20% | |||
| Normalized Basic EPS | 9.81% | 6.19% | |||
| EPS Diluted | 9.81% | 6.20% | |||
| Normalized Diluted EPS | 9.81% | 6.19% | |||
| Average Basic Shares Outstanding | 28.55% | 7.85% | |||
| Average Diluted Shares Outstanding | 28.55% | 7.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||